Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 10/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 8/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405170 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL7550784 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4158769 | 0.96 | CYP3A4 (0.93) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1817264 | 0.95 | CYP3A4 (0.90) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7854644 | 0.94 | CYP3A4 (0.88) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816215 | 0.93 | CYP3A4 (0.86) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4591080 | 0.91 | CYP3A4 (0.84) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4880932 | 0.91 | CYP3A4 (0.84) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4170085 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7853549 | 0.91 | CYP3A4 (0.82) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150086497-A1 | Skin Lightening Compositions | ELC MAN LLC (US) | 2015-03-26 | — | — | US | claimed |
| WO-2013130407-A1 | SMALL MOLECULE INHIBITORS OF P-TYPE ATPASES | ELC MANAGEMENT LLC (US) | 2013-09-06 | — | — | WO | claimed |
| US-20130231372-A1 | Small Molecule Inhibitors Of P-type ATPases | ELC MANAGEMENT LLC | 2013-09-05 | — | — | US | claimed |
| US-20080280944-A1 | Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1974730-A1 | Imidazo[1,2-a]pyridine derivatives for use in the treatment of sleep disturbance due to silent gastro-esophageal reflux | AstraZeneca AB (SE) | 2008-10-01 | — | — | EP | claimed |
| US-20080118560-A1 | Spray congealed 5-amido-7-benzyl(oxy or amino)imidazo[1,2-a]pyridines, at least one each of hydrophilic and hydrophobic matrix formers; antisecretory agents with improved water solubility, bioavailability and pharmacokinetics | JUPPO ANNE | 2008-05-22 | — | — | US | claimed |
| US-20080102133-A1 | Oral Pharmaceutical Preparation for Proton Pump Antagonists | ALTANA PHARMA AG (DE) | 2008-05-01 | — | — | US | claimed |
| US-20080050428-A1 | Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient | ALTANA PHARMA AG (DE) | 2008-02-28 | — | — | US | claimed |
| EP-1799190-A1 | ORAL PHARMACEUTICAL PREPARATION FOR PROTON PUMP ANTAGONISTS | Altana Pharma AG (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1799211-A1 | ORAL PHARMACEUTICAL PREPARATION COMPRISING A PROTON PUMP ANTAGONIST AND A BASIC EXCIPIENT | Altana Pharma AG (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1361868-A1 | NOVEL MODIFIED RELEASE FORMULATION | AstraZeneca AB (SE) | 2003-11-19 | — | — | EP | claimed |
| WO-2003043614-A2 | REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-05-30 | — | — | WO | claimed |
| WO-2002064118-A1 | NOVEL MODIFIED RELEASE FORMULATION | ASTRAZENECA AB (SE) | 2002-08-22 | — | — | WO | claimed |
| WO-2002060442-A1 | NOVEL FORMS OF 2,3-DIMETHYL-8-(2-ETHYL-6-METHYLBENZYLAMINO)-IMIDAZO (1,2-A)PYRIDINE-6-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | claimed |
| WO-2002060441-A1 | NOVEL FORMS OF 2,3-DIMETHYL-8-(2-ETHYL-6-METHYLBENZYLAMINO)-IMIDAZO (1,2-A)PYRIDINE-6-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | claimed |
| WO-2002060440-A1 | NOVEL FORMS OF 2,3-DIMETHYL-8-(2-ETHYL-6-METHYLBENZYLAMINO)-IMIDAZO (1,2-A)PYRIDINE-6-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | claimed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | claimed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | claimed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080118560-A1 | Spray congealed 5-amido-7-benzyl(oxy or amino)imidazo[1,2-a]pyridines, at least one each of hydrophilic and hydrophobic matrix formers; antisecretory agents with improved water solubility, bioavailability and pharmacokinetics | ABCB11, SLC7A1, CYP7A1 | CYP3A4 157/4885CYP2C9 439/4885CYP2D6 239/4885 |
| US-20130231372-A1 | Small Molecule Inhibitors Of P-type ATPases | ATP6AP1, ATP5ME, ATP6V1E1 | CYP3A4 3000/4885CYP2C9 2610/4885CYP2D6 1715/4885 |
| US-20080280944-A1 | Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux | GIPR, GRPR, HRH2 | CYP3A4 255/4885CYP2C9 1059/4885CYP2D6 875/4885 |
| US-20150086497-A1 | Skin Lightening Compositions | CUTA, TYR, DSG1 | CYP3A4 2827/4885CYP2C9 2552/4885CYP2D6 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.